Total
0
Shares
BARD1 (ASX:BD1) - CEO, Dr Leearne Hinch
CEO, Dr Leearne Hinch
Sourced: Proactive Investors Australia
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cancer diagnostics developer BARD1 Life Sciences (BD1) has signed a consultancy and research agreement with Griffith University
  • Under the agreement, Griffith’s Mucosal Immunology Research Group will provide support for the development and commercialisation of BARD1 tech
  • BARD1’s particular focus is on autoantibody tests for the early detection of ovarian, breast and lung cancers
  • The MIRG’s advanced lab systems will help BARD1 perfect its novel diagnostic technology and potentially streamline its pathway to market
  • BARD1 is up 9.5 per cent in early trade, with shares priced at 2.3 cents each

Cancer diagnostics developer BARD1 Life Sciences (BD1) has signed a consultancy and research agreement with Griffith University’s Mucosal Immunology Research Group (MIRG).

Under the terms of the agreement, Griffith’s MIRG will provide support for the development and commercialisation of BARD1 technology in the detection of ovarian, breast and lung cancer.

BARD1’s Mission

BARD1 specialises in non-invasive diagnostic tests for the early detection of cancer. The company says its mission is to find new ways to detect and prevent cancer to improve patients’ lives.

BARD1 is currently developing a proprietary tumour marker platform – a technology which will help identify tumours earlier, and do so without invasive surgical biopsies. The new tech has potential diagnostic and therapeutic applications across multiple cancers. BARD1’s particular focus is on autoantibody tests in development for early detection of ovarian, breast and lung cancers.

The Merger with MIRG

The Mucosal Immunology Research Group is focused on understanding the role of the immune system in human health and disease. Headquartered within the Menzies Health Institute at Griffith University, this focus is achieved through a range of pre-clinical and clinical research initiatives in partnership with clinicians and commercial partners.

The MIRG’s expertise in laboratory and diagnostic testing will help BARD1 define and refine how its advanced diagnostic technology is performing, and how it can be perfected. The MIRG’s specialised data capture and analytics will underpin the advancement of BARD1’s novel technology.

A New Hope

The new partners hope MIRG’s laboratory expertise in analysing and quantifying immune responses will fast-track BARD1’s pathway to the commercialisation of its tech.

BARD1 CEO Dr Leearne Hinch says the MIRG partnership is an ideal fit for the company’s growth and development strategy.

“[The partnership] provides the company with local access to additional expertise in immunoassay development and performance, biostatistical analysis and critical biospecimens for future clinical validation studies as we advance our diagnostic programs towards commercialisation,” Leearne explained.

BARD1 is currently based in Perth, WA, but its research arm has been working out of Geneva, Switzerland. In fostering the collaboration with Griffith, BARD1 can move its entire operation to Australia’s east coast. This offers the opportunity to streamline its model and focus on delivering its technology to market.

BARD1 is up 9.5 per cent in early trade, with shares priced at 2.3 cents each as at 12:05 pm AEDT.

BD1 by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.